Akebia Therapeut SEC Filings

An unnamed holder of Akebia Therapeutics, Inc. common stock has filed a notice to sell 69772 shares under Rule 144. The planned sale, with an aggregate market value of 97297.00, is to be executed through Morgan Stanley Smith Barney LLC on the Nasdaq around 02/02/2026. The securities are restricted stock originally acquired from Akebia on 01/31/2026, and the filing notes that total common shares outstanding are 265365993.

Akebia Therapeutics entered into a long-term lease to relocate its corporate headquarters to new office and lab space in Waltham, Massachusetts. The lease covers approximately 43,474 square feet and includes an initial annual rent of $898,317 for the office area and $1,046,920 for the lab area, subject to scheduled yearly increases. The initial term runs 84 months from the office commencement date, with a security deposit of $810,515 provided via letter of credit and an option for a five-year extension.

Akebia also approved amended executive severance agreements for its CEO, John P. Butler, and CFO, Erik J. Ostrowski, to better align with market practices. These agreements provide specified periods of salary continuation, bonus payments, COBRA premium reimbursements, and accelerated vesting of equity awards upon certain terminations, particularly in connection with a change in control, contingent on a release of claims and ongoing restrictive covenants.

BlackRock, Inc. filed an amended Schedule 13G reporting its beneficial ownership of common stock of Akebia Therapeutics, Inc. as of 12/31/2025. BlackRock reports beneficial ownership of 19,219,819 Akebia shares, representing 7.2% of the outstanding common stock. It has sole voting power over 18,844,036 shares and sole dispositive power over 19,219,819 shares, with no shared voting or dispositive power.

The filing explains that these holdings are attributed to certain BlackRock business units and are held in the ordinary course of business, not for the purpose of changing or influencing control of Akebia. Various underlying clients have rights to dividends or sale proceeds, but no single person has more than 5% of Akebia’s outstanding common shares.

Akebia Therapeutics, Inc. furnished an update focused on its Vafseo® (vadadustat) commercial business and future growth plans. The company issued a press release outlining key corporate updates, an outlook on upcoming milestones, and highlighted its next anticipated growth driver in its mid-stage rare kidney disease pipeline. It also shared an overview of expected fourth quarter 2025 Vafseo net product revenue.

Akebia is also making a corporate presentation available, which its spokespersons plan to use at investor and analyst meetings, including sessions coinciding with the 44th Annual J.P. Morgan Healthcare Conference. Both the press release and the presentation are attached as exhibits and are being furnished, not filed, under the securities laws.

Akebia Therapeutics, Inc. entered into an amendment to its existing license agreement with Medice Arzneimittel Putter GmbH & Co. KG related to Vafseo, its treatment for anemia in chronic kidney disease. The amendment, dated November 12, 2025, adds a new supply and manufacturing structure.

Under the amendment, Akebia will supply vadadustat drug substance to Medice under a separate supply agreement, and Medice is granted the right to manufacture Vafseo tablets using that material. Any new know-how or patent rights that arise from Medice’s manufacturing activities will be owned by Akebia, helping Akebia retain control over future intellectual property linked to Vafseo tablet production in the licensed territories.

Akebia Therapeutics reported Q3 2025 results showing higher revenue and a small profit. Total revenue was $58.8 million versus $37.4 million a year ago, driven by product revenue of $56.8 million. Net income was $0.5 million for the quarter; for the nine months, net income was $6.9 million versus a $46.6 million loss last year.

Cash and cash equivalents were $166.4 million as of September 30, 2025. Total assets were $364.2 million and stockholders’ equity improved to $41.6 million from a deficit at year-end 2024. The company launched Vafseo in the U.S. in January 2025, while Auryxia lost U.S. exclusivity in March 2025, with generic competition noted as an ongoing risk.

Akebia’s BlackRock term loan bears interest at SOFR (1‑month) plus 6.75% (all-in capped at 15.00%), with interest-only payments through December 31, 2026 and covenants requiring either a $15.0 million minimum cash balance in controlled accounts or $150.0 million of trailing twelve‑month revenue.

Akebia Therapeutics, Inc. filed a current report to furnish a press release announcing its financial results for the third quarter ended September 30, 2025 and recent business highlights. The company issued the press release on November 10, 2025, and attached it as Exhibit 99.1. The report clarifies that the information in Item 2.02 and Exhibit 99.1 is being furnished rather than filed under the Exchange Act, so it is not subject to Section 18 liability and will only be incorporated into other SEC filings if specifically referenced. Akebia’s common stock, par value $0.00001 per share, trades on The Nasdaq Capital Market under the symbol AKBA.

Akebia Therapeutics (AKBA) announced a strategic setback. After meeting with the U.S. Food and Drug Administration, the company did not reach alignment on the design of the VALOR clinical trial evaluating vadadustat for anemia in late-stage chronic kidney disease patients not on dialysis. As a result, Akebia does not plan to initiate VALOR and does not expect to pursue a broad U.S. label for Vafseo in non-dialysis dependent CKD.

This decision narrows the company’s near-term U.S. regulatory path for vadadustat in the non-dialysis setting and shifts focus away from a broad label expansion. The disclosure was made under Regulation FD and as an Other Event, highlighting its significance to the company’s clinical and commercial strategy.